If you have been reading about AEDG and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Computed for the free acid of Ala-Glu-Asp-Gly |
| Molecular mass | About 390.35 g/mol | Free peptide; salt forms shift the value |
| Appearance | White to off-white solid | Typical of short peptides after freeze-drying |
| Solubility class | Freely soluble in water | Aqueous buffers are also commonly used |
| Common synonyms | Epitalon, epithalone, AEDG | AEDG is the single-letter sequence |
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
== Coffee consumption == As of 2015, there were an estimated 49,600 coffee shops in South Korea, and 17,000 coffee shops in Seoul, making Seoul's coffee-per-capita greater than that of Seattle or San Francisco. The number of coffee shops in South Korea later surpassed 100,000, reaching 100,729 by the end of 2022 according to Statistics Korea—nearly double the combined number of outlets of the country's four largest convenience store chains. South Korea's per capita coffee consumption was estimated at 405 cups per year in 2023, and at 416 cups in 2024, the highest among Asian countries. The instant coffee market makes up a large percentage of the total coffee consumption in Korea where many well-known brands compete for market share. Instant coffee technology like freeze-drying, which was the best method of preserving the flavor of coffee, was improved upon in Korea, where freeze-drying was stabilized for mass production. As of 2003, instant coffee made up 90 percent of all the coffee consumed. With the introduction of big coffee chains like Starbucks, in the late 1990s, the consumption of freshly brewed coffee increased. Going to Starbucks to enjoy coffee became a way to engage with American and Western culture, hence many young and/or middle and upper-middle class Koreans began to frequent Starbucks.
=== Other explanations === In the UK, psychiatrist Kingsley Jones sees the support of the Board of Control as important in persuading psychiatrists to use insulin coma therapy. The treatment then acquired the privileged status of a standard procedure, protected by professional organizational interests. He also notes that it has been suggested that the Mental Treatment Act 1930 encouraged psychiatrists to experiment with physical treatments. British lawyer Phil Fennell notes that patients "must have been terrified" by the insulin coma therapy procedures and the effects of the massive overdoses of insulin, and were often rendered more compliant and easier to manage after a course. Leonard Roy Frank, an American activist from the psychiatric survivors movement who underwent 50 forced insulin coma treatments combined with ECT, described the treatment as "the most devastating, painful and humiliating experience of my life", a "flat-out atrocity" glossed over by psychiatric euphemism, and a violation of basic human rights. In 2013, French physician-and-novelist Laurent Seksik wrote a historical novel about the tragic life of Eduard Einstein: Le cas Eduard Einstein. He related the encounter between Dr Sakel and Mileva Maric, Albert Einstein's first wife (and Eduard's mother), and the way Sakel's therapy had been given to Eduard, who had schizophrenia.
Estrogens, in females, are produced primarily by the ovaries, and during pregnancy, the placenta. Follicle-stimulating hormone (FSH) stimulates the ovarian production of estrogens by the granulosa cells of the ovarian follicles and corpora lutea. Some estrogens are also produced in smaller amounts by other tissues such as the liver, pancreas, bone, adrenal glands, skin, brain, adipose tissue, and the breasts. These secondary sources of estrogens are especially important in postmenopausal women. The pathway of estrogen biosynthesis in extragonadal tissues is different. These tissues are not able to synthesize C19 steroids, and therefore depend on C19 supplies from other tissues and the level of aromatase. In females, synthesis of estrogens starts in theca interna cells in the ovary, by the synthesis of androstenedione from cholesterol. Androstenedione is a substance of weak androgenic activity which serves predominantly as a precursor for more potent androgens such as testosterone as well as estrogen. This compound crosses the basal membrane into the surrounding granulosa cells, where it is converted either immediately into estrone, or into testosterone and then estradiol in an additional step. The conversion of androstenedione to testosterone is catalyzed by 17β-hydroxysteroid dehydrogenase (17β-HSD), whereas the conversion of androstenedione and testosterone into estrone and estradiol, respectively is catalyzed by aromatase, enzymes which are both expressed in granulosa cells.
== Overview == The pharmaceutical market uses outsourcing services from providers in the form of contract research organizations (CROs) who work on very early-stage drug development on very small scale providing medicinal chemistry services. These are now often called CDROs as they provide some small scale development work. CDMOs work on the scale-up and later stages of drug development often preparing materials ranging from hundreds of grams to multi-kilo amounts. As the drug moves through the various clinical stages, the volumes tend to grow as well. Commercial scale amounts could range to metric tons. Over the years, the concept of a comprehensive single-source provider from drug development (a one-stop shop) through commercial manufacture of drug substance and drug product has been tried to varying success. CDMOs are a response to the competitive international nature of the pharmaceutical market as well as the increasing demand for outsourced services. The best-positioned service providers focus on a specific technology or dosage form and promote end-to-end continuity and efficiency for their outsourcing clients. With lower-cost international manufacturers capturing an increasing percentage of the contract manufacturing market, specialization may be an effective hedge against loss of market share.
Sources: en.wikipedia.org
The newest formulation to come out was in 2014 when zohydro, an increased dosage formula of hydrocodone, was released; this is so far the strongest hydrocodone formulation created for pain management, on par with a moderate dose of oxycodone .
Moreover, not only has bicalutamide been found not to reduce levator ani weight or lean body mass in male rats at doses that are potently antiandrogenic in the prostate, the drug has been found to partially antagonize castration-induced body weight loss and lean body mass loss in male rats. This effect also occurred with JNJ-26146900, a SARM, and with DHT, although neither JNJ-26146900 nor bicalutamide were as effective as DHT at preserving body weight or lean mass. As such, on the basis of such preclinical findings, it has been said that bicalutamide does not have marked antianabolic effects in muscle, and hence shows tissue selectivity in its antiandrogenic actions. Moreover, bicalutamide may also actually activate the AR in muscle to preserve muscle mass. If these findings were to translate to humans, then bicalutamide would inhibit prostate cancer growth without the antiandrogenic muscle atrophy that occurs with castration. Analogously to the animal findings, high-dose bicalutamide monotherapy has been found to preserve lean muscle mass and muscle strength in men with prostate cancer relative to GnRH agonists. Androgens are known to exert direct effects on bone remodeling through activation of ARs in osteoblasts and osteoclasts. In relation to this, androgen deprivation therapy for prostate cancer has been associated with osteopenia. It has been found that bicalutamide monotherapy, in spite of its antiandrogenic activity, does not affect bone remodeling or bone mineral density in healthy male rats.
=== SGLT inhibition === McGuire is known for his research on sodium-glucose cotransporter-2 (SGLT2) and SGLT1/2 inhibitors. McGuire has had consultancy and/or trial leadership roles for all SGLT inhibitors presently available for clinical use in the US, and he has contributed to iterative meta-analyses of randomized CVOT trials data on SGLT2 and SGLT1/2 inhibitors. These analyses found that SGLT inhibitors reduce the risk of MACE, hospitalization for heart failure, and progression of chronic kidney disease. The benefits were consistent across patients with and without type 2 diabetes and across varying levels of cardiovascular and kidney risk.
Silica gel particles have a high surface area for interactions to take place, either with solutes or bonding with ligands. Silica gel does not react with many types of solvents and analytes. Silica gel can be modified with various functional groups. Silica gel is cheap. Silica gel particles are easy to engineer into specific diameters, shapes, pore sizes, etc. The silica particle can have different shapes. The particle can be fully solid ("monolithic" or "fused"), full of holes ("porous"), or have a solid core and a porous shell ("superficially porous"). The particle can have different diameters. The pores can have different diameters. The United States Pharmacopoeia (USP) has classified HPLC columns by L# types. The most popular column in this classification is an octadecyl carbon chain (C18)-bonded silica (USP classification L1). This is followed by C8-bonded silica (L7), pure silica (L3), cyano-bonded silica (CN) (L10) and phenyl-bonded silica (L11). Note that C18, C8 and phenyl are dedicated reversed-phase stationary phases, while CN columns can be used in a reversed-phase mode depending on analyte and mobile phase conditions. Not all C18 columns have identical retention properties. Surface functionalization of silica can be performed in a monomeric or a polymeric reaction with different short-chain organosilanes used in a second step to cover remaining silanol groups (end-capping). While the overall retention mechanism remains the same, subtle differences in the surface chemistries of different stationary phases will lead to changes in selectivity.
Plasmin is an important enzyme (EC 3.4.21.7) present in blood that degrades many blood plasma proteins, including fibrin clots. The degradation of fibrin is termed fibrinolysis. In humans, the plasmin protein (in the zymogen form of plasminogen) is encoded by the PLG gene.
Sources: en.wikipedia.org
=== Phase 1 === Etifoxine deuterated (deuterated etifoxine; GRX-917) – GABAA receptor positive allosteric modulator, translocator protein (TSPO) agonist, and nonbenzodiazepine/benzoxazine [12] KAR-2618 (GFB-887; TRPC4/5 inhibitor) – transient receptor potential TRPC4 and TRPC5 cation channel inhibitor [13] SNTX-2643 (SENS-01) – atypical serotonin reuptake inhibitor (SRI) (kanna-derived) [14] Transient receptor potential channel 4/5 inhibitor - Bristol-Myers Squibb – transient receptor potential TRPC4 and TRPC5 cation channel inhibitor [15]
== Perception thresholds == Safety limits exist for microwave exposure. The U.S. Occupational Safety and Health Administration defines energy density limit for exposure periods of 0.1 hours or more to 10 mW/cm2; for shorter periods the limit is 1 mW-hr/cm2 with limited excursions above 10 mW/cm2. The U.S. Food and Drug Administration (FDA) standard for microwave oven leakage puts limit to 5 mW/cm2 at 2 inches from the oven's surface. For 5.8 GHz, exposure to 30 mW/cm2 causes increase of facial skin temperature by 0.48 °C, corneal surface heats by 0.7 °C, and the temperature of retina is estimated to increase by 0.08–0.03 °C. Exposure of skin to microwaves can be perceived as a sensation of heat or pain. Due to lower penetration of higher frequencies, perception threshold is lower for higher frequencies as more energy is dissipated closer to the body surface. When the entire face is exposed to 10 GHz microwaves, the feeling of heat is evoked at energy densities of 4–6 mW/cm2 for 5 or more seconds, or about 10 mW/cm2 for a half second. Experiments on six volunteers exposed to 2.45 GHz microwaves shown perception thresholds on forearm skin to be at the average of 25–29 mW/cm2, ranging from 15.40 to 44.25 mW/cm2. The sensation was indistinguishable from heat delivered by infrared radiation, though the infrared radiation required about five times lower energy density.
Blood smear to evaluate cell morphology Iron panel to evaluate for concurrent iron deficiency JAK2 mutation testing Serum erythropoeitin (EPO) levels Oxygen saturation (usually via pulse oximetry or blood gas tests) or oxygen dissociation tests
=== Biosynthesis === Almost all animal tissues synthesize cholesterol from acetyl-CoA. All animal cells (with some exceptions within the invertebrates) manufacture cholesterol, for both membrane structure and other uses, with relative production rates varying by cell type and organ function. About 80% of total daily cholesterol production occurs in the liver and the intestines; other sites of higher synthesis rates include the brain, the adrenal glands, and the reproductive organs. Synthesis within the body starts with the mevalonate pathway where two molecules of acetyl-CoA condense to form acetoacetyl-CoA. This is followed by a second condensation between acetyl-CoA and acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl CoA (HMG-CoA).
Sources: en.wikipedia.org
It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.
Epitalon and epithalon both circulate, and the difference reflects transliteration of a name coined in Russian-language publications. Reference to the extract it derives from, epithalamin, explains the shared stem. Databases and suppliers are inconsistent, so a search for one spelling alone may miss relevant entries.
No. Epithalamin is a multi-component preparation obtained from pineal tissue, and its exact composition is not fully characterised. Epitalon is a single defined tetrapeptide described as a short synthetic counterpart of that extract, so the two are related in origin but not interchangeable in identity.
Sealed lyophilised powder is normally kept at minus twenty degrees Celsius or below, away from light and moisture. Vials are allowed to reach room temperature before opening to limit condensation. Repeated warming and cooling of the same vial is discouraged.